Published: 22 December 2021
Author(s): Paul Decker, Vincent Sobanski, Thomas Moulinet, David Launay, Eric Hachulla, Victor Valentin, Benoit Godbert, Sabine Revuz, Anne Guillaumot, Emmanuel Gomez, François Chabot, Lidwine Wémeau, Roland Jaussaud
Issue: March 2022
Section: Original article

Interstitial lung diseases (ILD) are a heterogenous group of diseases characterized by diffuse abnormal deposition of collagen matrices in the pulmonary parenchyma [1,2]. Interstitial lung diseases (ILD) represent a frequent complication of connective tissue diseases (CTD), especially in systemic sclerosis (SSc) (55–65% of patients), idiopathic inflammatory myopathies (15–35% of patients) and rheumatoid arthritis (RA) (almost 30% of patients) [3–6]. ILD remains a cause of significant morbidity and mortality in patients with CTD [7].


Stay informed on our latest news!